Skip to content
thestock.space

On 6 Nov 2026, Kwality Pharmaceuticals was priced at ₹3,644.80, or 46.7× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 26% and 51% a year over 3 years, with ROCE of 27% and ROE of 23%. Debt is 0.40× equity. It is a small-cap company with a market cap of ₹3,782 Cr, ranked 49th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 3.2% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹3,699.50
Day high
₹3,724.20
Day low
₹3,553.10
Prev. close
₹3,687.30
Volume
20.6K

Health check

3 good · 3 to check
  • ReturnsBehind

    +3.2% over a year, better than 1 of 7 peers.

  • Price tagPricier

    P/E 46.7 vs industry 28.7.

  • GrowthStrong

    Sales +26.1%, profit +51.5% a year over 3 years.

  • ProfitabilityStrong

    ROCE 27.4% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.40× equity, interest covered 10.8×.

  • Red flags1 to check

    P/E of 46.7 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹3,782 Cr, #49 of 154 in its industry by size.

Defensive

Beta 0.77 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹554 Cr · profit ₹81 Cr
Market cap
₹3,782 Cr
Small cap
P/E
46.7
Industry 28.7
Price to book
11.41
Peers 4.99
Dividend yield
0.00%
ROE
22.6%
Peers 14.7%
ROCE
27.4%
Peers 17.9%
Debt to equity
0.40
Debt ₹131 Cr
EPS (TTM)
₹78.10
Face value ₹10
OPM (TTM)
24.4%
Net margin 14.6%
Sales growth
+45.6%
Latest quarter vs a year ago
Profit growth
+114.9%
Latest quarter vs a year ago
Price to sales
6.83
EV/EBITDA 28.4

Strengths and risks

Strengths

  • Return on equity of 22.6%.
  • Return on capital employed of 27.4%.
  • Quarterly profit up 114.9% on a year ago.
  • Quarterly sales up 45.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 46.7 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Kwality Pharmaceuticals

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam,…

Headquarters
Amritsar
Employees
1,137
Sector
Healthcare
ISIN
INE552U01010
Website
kwalitypharma.com

Price range

52 weeks

₹3,137.00₹3,949.00

Today

₹3,553.10₹3,724.20
Avg volume (3M)
38.2K
1-year return
plus 3.2%
From 52-week high
minus 7.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
KPLKwality Pharmaceuticals3,644.80minus 1.15%3,78246.711.41–24.4%24.4%––0.00%plus 3.2%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
111111123157162
87.385.793.5118121
24.225.43038.841
21.7%22.8%24.3%24.7%25.3%
0.40.90.51.10.6
2.82.82.52.92.7
4.854.85.35
––−0.8––
1718.522.331.734
30.0%23.5%28.4%20.1%24.6%
11.914.11625.325.6
11.4913.6015.4224.3924.69

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+26.1%
Profit CAGR 3Y
+51.5%
EPS CAGR 3Y
+51.5%
ROE
22.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
251307370503
–+22.3%+20.6%+35.9%
204241290385
46.666.380.4118
18.5%21.6%21.7%23.5%
16.51.81.92.1
610.49.911
1519.618.319.8
−16.5−7.10−0.1
25.631.154.189.5
24.6%24.1%26.5%24.7%
19.423.839.867.3
–+22.8%+67.4%+69.0%
18.6722.9338.4064.90

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.410.410.410.4
190214254321
90.398.1112131
62.971.970.8130
354394447592
145150156177
24.211.411.527.1
7.45.914.83.6
177226265385
354394447592

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
41.44352.716.6
−48.4−26.4−28.5−34.9
1−17.4−14.47
−6.1−0.89.8−11.3
−47.7−29.8−25−48.9
−6.313.127.7−32.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 0.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you